What smart money is saying about Theravance Biopharma
TBPH
No fund has written a full thesis on Theravance Biopharma in our archive, but 1 fund letter reports a position in it — most recently Laughing Water Capital (LW Capital Management, LLC) in June 2026.
Get an email when a fund writes about it
1
Reported positions
0
Bought
1
Sold
1
Letter
Position history
Every position in Theravance Biopharma on record in the archive was reported in Q2 2026, across 1 fund letter — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 1 | 0 |
Fund activity · 1 position · 1 move
- June 2026
“Most notable is our investment in Theravance Biopharma (TBPH), which was introduced in our Q1’26 letter. Following the failure of a Phase III drug trial the company was a special situation tied to a drug-related royalty stream, and the company announced that a strategic review committee was considering all options to create value for shareholders. I believed the most likely outcome would be a sale of the company at a price somewhere between $17 and $25 at some point in the next few months. News of a sale came in near quarter end at the low end of my expected range.”
Theravance Biopharma
Read the letters behind these Theravance Biopharma positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves — and to Warren AI, which reads all of them for you.
View plans→Share this ledger